World Pharma News Digest - 15.04.2014
7 views
Skip to first unread message
Ruslan David
Apr 15, 2014, 5:16:04 AM4/15/14
to worldph...@googlegroups.com
Enzyme revealed as promising target to treat asthma and cancer
In experiments with mice, Johns Hopkins Kimmel Cancer Center scientists have identified an enzyme involved in the regulation of immune system T cells that could be a useful target in treating asthma and boosting the effects of certain cancer therapies. In research described online April 6 in Nature Immunology, the investigators show that mice without the enzyme SKG1 were resistant to dust mite-induced asthma.
Read more...
http://www.worldpharmanews.com/research/2754-enzyme-revealed-as-promising-target-to-treat-asthma-and-cancer
Virus-fighting genes linked to mutations in cancer
Researchers have found a major piece of genetic evidence that confirms the role of a group of virus-fighting genes in cancer development. Our understanding of the biological processes that cause cancer is limited. UV light and smoking are two well-understood cancer-causing processes. Exposure to either of these processes causes distinguishable patterns of genetic damage, or 'signatures', on the genome that can lead to cancer.
Read more...
http://www.worldpharmanews.com/research/2753-virus-fighting-genes-linked-to-mutations-in-cancer
Yeast provides genetic clues on drug response
Why do people respond differently to the same drug? For the first time, researchers have untangled genetic and environmental factors related to drug reactions, bringing us a step closer to predicting how a drug will affect us. Researchers at the University of British Columbia exposed 6,000 strains of yeast to 3,000 drugs. Yeast strains were modified so their response could be measured.
Read more...
http://www.worldpharmanews.com/research/2752-yeast-provides-genetic-clues-on-drug-response
Abbott completes enrollment of Absorb™ randomized clinical trials in the United States, Japan and China
Abbott (NYSE: ABT) today announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb™ Bioresorbable Vascular Scaffold (BVS) in the United States, Japan and China. Combined, the U.S., Japan and China account for more than 50 percent of the world's heart stent market.
Read more...
http://www.worldpharmanews.com/abbott/2751-abbott-completes-enrollment-of-absorb-randomized-clinical-trials-in-the-united-states-japan-and-china
Cancer's thirst for copper can be targeted
Drugs used to block copper absorption for a rare genetic condition may find an additional use as a treatment for certain types of cancer, researchers at Duke Medicine report. The researchers found that cancers with a mutation in the BRAF gene require copper to promote tumor growth. These tumors include melanoma, the most dangerous form of skin cancer that kills an estimated 10,000 people in the United States a year, according to the National Cancer Institute.
Read more...
http://www.worldpharmanews.com/research/2750-cancers-thirst-for-copper-can-be-targeted
Experimental drug shows promise for treatment-resistant leukemias
Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia. Results of the research by Johns Hopkins Kimmel Cancer Center investigators, described March 6 in the journal Blood, show that two doses a day of TTT-3002 eliminated leukemia cells in a group of mice within 10 days.
Read more...
http://www.worldpharmanews.com/research/2749-experimental-drug-shows-promise-for-treatment-resistant-leukemias
Caffeine against Alzheimer's disease
As part of a German-French research project, a team led by Dr. Christa E. Müller from the University of Bonn and Dr. David Blum from the University of Lille was able to demonstrate for the first time that caffeine has a positive effect on tau deposits in Alzheimer's disease. The two-years project was supported with 30,000 Euro from the non-profit Alzheimer Forschung Initiative e.V. (AFI) and with 50,000 Euro from the French Partner organization LECMA.
Read more...
http://www.worldpharmanews.com/research/2748-caffeine-against-alzheimers-disease
PharmaNews.eu / Latest News
Positive trial data suggests Exenatide has the potential to be a disease modifying agent in Parkinson's disease
http://www.pharmanews.eu/research-and-development/1434-positive-trial-data-suggests-exenatide-has-the-potential-to-be-a-disease-modifying-agent-in-parkinsons-disease
Novartis announces that the XOVA (eXcellence in Ophthalmology Vision Award) is now open for entries
http://www.pharmanews.eu/novartis/1433-novartis-announces-that-the-xova-excellence-in-ophthalmology-vision-award-is-now-open-for-entries
Unexpected results in cancer drug trial
http://www.pharmanews.eu/research-and-development/1432-unexpected-results-in-cancer-drug-trial
Novel plant biotechnology approach for sustainable production of pharmaceutical compounds
http://www.pharmanews.eu/research-and-development/1431-novel-plant-biotechnology-approach-for-sustainable-production-of-pharmaceutical-compounds
Choices in TB vaccine development
http://www.pharmanews.eu/research-and-development/1430-choices-in-tb-vaccine-development
Nanoparticles cause cancer cells to self-destruct
http://www.pharmanews.eu/research-and-development/1429-nanoparticles-cause-cancer-cells-to-self-destruct
UCB CEO, Roch Doliveux, to chair Innovative Medicines Initiative board for a second term
http://www.pharmanews.eu/research-and-development/1428-ucb-ceo-roch-doliveux-to-chair-innovative-medicines-initiative-board-for-a-second-term
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
In experiments with mice, Johns Hopkins Kimmel Cancer Center scientists have identified an enzyme involved in the regulation of immune system T cells that could be a useful target in treating asthma and boosting the effects of certain cancer therapies. In research described online April 6 in Nature Immunology, the investigators show that mice without the enzyme SKG1 were resistant to dust mite-induced asthma.
Read more...
http://www.worldpharmanews.com/research/2754-enzyme-revealed-as-promising-target-to-treat-asthma-and-cancer
Virus-fighting genes linked to mutations in cancer
Researchers have found a major piece of genetic evidence that confirms the role of a group of virus-fighting genes in cancer development. Our understanding of the biological processes that cause cancer is limited. UV light and smoking are two well-understood cancer-causing processes. Exposure to either of these processes causes distinguishable patterns of genetic damage, or 'signatures', on the genome that can lead to cancer.
Read more...
http://www.worldpharmanews.com/research/2753-virus-fighting-genes-linked-to-mutations-in-cancer
Yeast provides genetic clues on drug response
Why do people respond differently to the same drug? For the first time, researchers have untangled genetic and environmental factors related to drug reactions, bringing us a step closer to predicting how a drug will affect us. Researchers at the University of British Columbia exposed 6,000 strains of yeast to 3,000 drugs. Yeast strains were modified so their response could be measured.
Read more...
http://www.worldpharmanews.com/research/2752-yeast-provides-genetic-clues-on-drug-response
Abbott completes enrollment of Absorb™ randomized clinical trials in the United States, Japan and China
Abbott (NYSE: ABT) today announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb™ Bioresorbable Vascular Scaffold (BVS) in the United States, Japan and China. Combined, the U.S., Japan and China account for more than 50 percent of the world's heart stent market.
Read more...
http://www.worldpharmanews.com/abbott/2751-abbott-completes-enrollment-of-absorb-randomized-clinical-trials-in-the-united-states-japan-and-china
Cancer's thirst for copper can be targeted
Drugs used to block copper absorption for a rare genetic condition may find an additional use as a treatment for certain types of cancer, researchers at Duke Medicine report. The researchers found that cancers with a mutation in the BRAF gene require copper to promote tumor growth. These tumors include melanoma, the most dangerous form of skin cancer that kills an estimated 10,000 people in the United States a year, according to the National Cancer Institute.
Read more...
http://www.worldpharmanews.com/research/2750-cancers-thirst-for-copper-can-be-targeted
Experimental drug shows promise for treatment-resistant leukemias
Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia. Results of the research by Johns Hopkins Kimmel Cancer Center investigators, described March 6 in the journal Blood, show that two doses a day of TTT-3002 eliminated leukemia cells in a group of mice within 10 days.
Read more...
http://www.worldpharmanews.com/research/2749-experimental-drug-shows-promise-for-treatment-resistant-leukemias
Caffeine against Alzheimer's disease
As part of a German-French research project, a team led by Dr. Christa E. Müller from the University of Bonn and Dr. David Blum from the University of Lille was able to demonstrate for the first time that caffeine has a positive effect on tau deposits in Alzheimer's disease. The two-years project was supported with 30,000 Euro from the non-profit Alzheimer Forschung Initiative e.V. (AFI) and with 50,000 Euro from the French Partner organization LECMA.
Read more...
http://www.worldpharmanews.com/research/2748-caffeine-against-alzheimers-disease
PharmaNews.eu / Latest News
Positive trial data suggests Exenatide has the potential to be a disease modifying agent in Parkinson's disease
http://www.pharmanews.eu/research-and-development/1434-positive-trial-data-suggests-exenatide-has-the-potential-to-be-a-disease-modifying-agent-in-parkinsons-disease
Novartis announces that the XOVA (eXcellence in Ophthalmology Vision Award) is now open for entries
http://www.pharmanews.eu/novartis/1433-novartis-announces-that-the-xova-excellence-in-ophthalmology-vision-award-is-now-open-for-entries
Unexpected results in cancer drug trial
http://www.pharmanews.eu/research-and-development/1432-unexpected-results-in-cancer-drug-trial
Novel plant biotechnology approach for sustainable production of pharmaceutical compounds
http://www.pharmanews.eu/research-and-development/1431-novel-plant-biotechnology-approach-for-sustainable-production-of-pharmaceutical-compounds
Choices in TB vaccine development
http://www.pharmanews.eu/research-and-development/1430-choices-in-tb-vaccine-development
Nanoparticles cause cancer cells to self-destruct
http://www.pharmanews.eu/research-and-development/1429-nanoparticles-cause-cancer-cells-to-self-destruct
UCB CEO, Roch Doliveux, to chair Innovative Medicines Initiative board for a second term
http://www.pharmanews.eu/research-and-development/1428-ucb-ceo-roch-doliveux-to-chair-innovative-medicines-initiative-board-for-a-second-term
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
Reply all
Reply to author
Forward
0 new messages